What Is the Value of Innovative Pharmaceutical Therapies in Oncology and Hematology? A Willingness-to-Pay Study in Bulgaria

Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge?

Hans‐Georg Eichler, Sheldon X. Kong, William C. Gerth et al. · Value in Health · 2004 · 803 citations · Full text

Pharmacy, Economics, Pharmacoeconomics +15

Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13

Courtney Davis, Huseyin Naci, Evrim Gurpinar et al. · BMJ · 2017 · 605 citations · Full text

Medicine, Oncology, Pharmacology +15

Performance-Based Risk-Sharing Arrangements—Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force

Louis P. Garrison, Adrian Towse, Andrew Briggs et al. · Value in Health · 2013 · 306 citations

Management, Performance Management, Risk Management +10

SOCIETAL VIEWS ON NICE, CANCER DRUGS FUND AND VALUE‐BASED PRICING CRITERIA FOR PRIORITISING MEDICINES: A CROSS‐SECTIONAL SURVEY OF 4118 ADULTS IN GREAT BRITAIN

Warren G. Linley, Dyfrig Hughes · Health Economics · 2012 · 207 citations

Pharmacy, Pharmaceutical Policy, Pharmacoeconomics +16

Do Oncologists Believe New Cancer Drugs Offer Good Value?

Eric Nadler, Ben Eckert, Peter J. Neumann · The Oncologist · 2006 · 185 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +14